Werewolf Therapeutics, Inc. (HOWL) Tops Q2 EPS by 28c

Werewolf Therapeutics, Inc. (NASDAQ: HOWL) reported Q2 EPS of ($0.14), $0.28 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $8.08 million versus the consensus estimate of $7.85 million.

For earnings history and earnings-related data on Werewolf Therapeutics, Inc. (HOWL) click here.

You May Also Be Interested In

• Werewolf Therapeutics, Inc. (HOWL) Tops Q2 EPS by 36c
• Contineum Therapeutics, Inc. (CTNM) Tops Q2 EPS by 4c
• Short sellers pile into SpaceX ahead of earnings, lockup expiration